GoodRx (GDRX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Jun, 2026Opening remarks and agenda
Meeting commenced with introductions of board members, officers, and the independent auditor in attendance.
Agenda and rules of conduct were made available on the virtual meeting webpage, with voting eligibility and procedures explained.
Board and executive committee updates
Wendy Barnes, Ronald E. Bruehlman, and Gregory Mondre were nominated for election as Class C directors for a term expiring at the 2029 annual meeting.
Board members and executive officers were introduced, including the CEO, CFO, and Chief Accounting Officer.
Shareholder proposals
Three proposals were presented: election of Class C directors, ratification of KPMG LLP as auditor, and advisory approval of executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from GoodRx
- Pharma Direct revenue soared 82% in Q1 2026, offsetting declines in other segments.GDRX
Q1 202612 May 2026 - Board recommends approval of all proposals at the virtual 2026 Annual Meeting.GDRX
Proxy filing29 Apr 2026 - Definitive additional proxy materials filed to inform shareholders of voting matters.GDRX
Proxy filing29 Apr 2026 - Sharpened strategy and robust growth in integrated savings and pharma solutions drive margin gains.GDRX
Morgan Stanley 22nd Annual Global Healthcare Conference5 Apr 2026 - Pharma Direct revenue surged 41% in 2025, driving growth despite headwinds in other segments.GDRX
Q4 202526 Feb 2026 - Q3 2025 saw strong manufacturer solutions growth and resilient financials amid industry headwinds.GDRX
Q3 20253 Feb 2026 - Q2 revenue up 6% to $200.6M, Adjusted EBITDA margin 32.6%, with cautious full-year outlook.GDRX
Q2 20242 Feb 2026 - Direct contracting, pharma partnerships, and PBM deals drive growth and competitive edge.GDRX
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 2024 revenue up 8%, net income $4.0M, and margin expansion driven by pharma solutions.GDRX
Q3 202416 Jan 2026